Target intelligence / Profile preview

Glutamyl-prolyl tRNA synthetase (EPRS1) (EPRS1)

Target
EPRS1
Molecular classification
Enzyme, Aminoacyl-tRNA synthetase, Ligase
01

Overview

Glutamyl-prolyl tRNA synthetase (EPRS1) is a bifunctional aminoacyl-tRNA synthetase that plays a critical role in protein translation by charging tRNA with glutamate and proline (UniProt P07814). It is unique in higher eukaryotes for containing two distinct catalytic domains—GluRS and ProRS—connected by a linker region that facilitates its incorporation into the multi-tRNA synthetase complex (MSC) (PubMed: 22327440). Beyond translation, EPRS1 is a key component of the GAIT complex, which regulates the translation of specific mRNAs involved in the inflammatory response (PubMed: 17210612). The ProRS domain is a validated therapeutic target for fibrotic diseases, as its inhibition triggers the amino acid starvation response (AAR) and selectively reduces the production of proline-rich proteins like Type I and Type III collagen (PubMed: 22327440). Small molecule inhibitors such as halofuginone and the clinical candidate bersiprosylline (DWN12088) compete with proline for the active site of the ProRS domain, offering a strategy to treat idiopathic pulmonary fibrosis and potentially certain cancers where EPRS1 is overexpressed (PubMed: 33536250).

Other names
Bifunctional aminoacyl-tRNA synthetaseProlyl-tRNA synthetaseGlutamate-tRNA ligaseProline-tRNA ligaseEPRSPIG32GLNRSProlyl-tRNA synthetase domain of glutamyl-prolyl tRNA synthetase
02

Mechanism of action

Competitive inhibition of the prolyl-tRNA synthetase domain, preventing the charging of tRNA with proline, which triggers the amino acid starvation response and selectively inhibits the translation of proline-rich proteins like collagen.

03

Biological functions

Protein biosynthesistRNA aminoacylationRegulation of translationInflammatory response regulation
04

Disease associations

FibrosisCancerIdiopathic pulmonary fibrosisAutoimmune disease
05

Safety considerations

Gastrointestinal toxicityPotential for general protein synthesis inhibitionOff-target effects on other tRNA synthetases
06

Interacting drugs

Halofuginone

3 more in the full profile.

07

Biomarkers

Pro-C3 (N-terminal propeptide of type III collagen)EPRS expression levelsIntracellular proline levels

Beyond the preview

Go deeper on Glutamyl-prolyl tRNA synthetase (EPRS1) (EPRS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamyl-prolyl tRNA synthetase (EPRS1) (EPRS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call